Pulmatrix Merges with Eos SENOLYTIX to Revolutionize Anti-Aging Treatments

Pulmatrix and Eos SENOLYTIX Forge a New Path in Anti-Aging Treatments

On March 26, 2026, Pulmatrix, Inc. announces a definitive merger with Eos SENOLYTIX, marking a significant development in the biotechnology sector focused on combating aging-related conditions. This merger creates Eos SENOLYTIX, a company poised to innovate in the field of gerotherapeutics with a primary focus on therapies targeting sarcopenia and sarcopenic obesity. As the world population ages, conditions like these become increasingly prevalent, highlighting an urgent need for effective treatments. With the merger set to close in mid-2026, this alliance has garnered unanimous approval from both companies' boards, setting the stage for a new phase in aging research and therapy development.

To facilitate their ambitious vision, Eos SENOLYTIX secures $19 million in private financing, which is earmarked for advancing the MitoXcel™ platform, along with PTC-2105, its lead clinical candidate. MitoXcel™ is anticipated to have a transformative impact by mitigating the adverse effects associated with muscle degradation due to aging. The financing is bolstered by a $1 million investment from RCM Eos PIPE HOLDINGS LLC, with additional bridge funding from RCM Eos Holdings, LLC. This financial backing not only underscores investor confidence but also provides the necessary resources to further accelerate the clinical development of therapies that could significantly enhance the quality of life for aging populations.

Post-merger, pre-merger shareholders of Pulmatrix are projected to retain a slender 6% stake in Eos SENOLYTIX, while Eos shareholders will control a commanding 94%. This delineation of ownership accentuates the strategic direction and focus of the new entity. By combining Pulmatrix’s innovative approach with Eos’s expertise in age-related treatments, the merged organization is uniquely positioned to push the boundaries in gerotherapeutics, potentially transforming how society addresses the biological processes of aging. As such, this merger does not merely signify a corporate maneuver but a pivotal step toward pioneering solutions in human health and longevity.

In parallel developments, the formation of Eos SENOLYTIX aptly illustrates the increasing trend in biotechnology collaborations aimed at addressing global health challenges associated with aging. The concerted efforts of Pulmatrix and Eos SENOLYTIX may herald new breakthroughs not only in therapeutic interventions but also in understanding the aging process itself, which continues to be a major focus of scientific inquiry and public health policy. By unlocking these complexities, the newly formed company endeavors to offer hope and improved wellness in the aging demographic, positioning itself as a leader in a rapidly evolving biotech landscape.